Lawyers for Plaintiffs and Defendants gave their closing arguments in the
first Levaquin trial of more than 2,600 claims nationwide.
Levaquin is an antibiotic marketed by Johnson & Johnson. Plaintiffs
argue that Johnson & Johnson should have warned consumers that Levaquin
had an increased risk of tendon damage and rupture prior to the FDA's
required "black box" warning added to the product label in 2008.
The "black box" warning states that the risk of tendon ruptures
is higher in patients older than 60, those taking steroids, and recipients
of kidney, heart or lung transplants.
The Levaquin case being tried involves Plaintiff John Schedin, 82, who
sued Johnson & Johnson in 2008 alleging he ruptured both of his Achilles
tendons after taking Levaquin. Mr. Schedin argues that his doctor have
prescribed another antibiotic had he known about the risks associated
The lawsuit is part of the multidistrict litigation for all federal court
Levaquin cases combined for trial in the United States District Court,
District of Minnesota.